Full-Time
Principal Process Engineer
Warehouse
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
Goldsboro, NC, USA
In Person
On-site in Wilson, NC; frequent travel (>75%) during design phase until plant site is operational.
Bachelor's, Master's, MBA
 Process Engineering |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- A minimum Bachelor’s degree in Engineering required
- Master’s degree or MBA preferred
- Minimum of 10 years logistics process engineering and/or capital project execution experience within a large-molecule, biotherapeutic cGMP environment
- Strong experience driving floorplan design for warehouse, material transport corridors, and in-process storage areas through simulation modeling, process mapping, and time studies to maximize flow efficiency
- Proven ability to build and maintain strong partnerships with cross-functional stakeholders
- Ability to lead and influence multicultural teams and remote collaborators
- Extensive interaction with external partners (A&E firms, construction teams, and equipment vendors) as a logistics process engineer
- Demonstrated strength in resolving complex technical and regulatory challenges impacting the equipment and facility design in logistics for large-molecule, biotherapeutic products
- Solid understanding of cGMP requirements for logistics of large-molecule biotherapeutic products
- Solid understanding of EHS requirements, with emphasis on EHS-by-design and construction safety
- Solid understanding of Start-up processes and Commissioning & Qualification for a large-scale biotherapeutic logistics operation
- Solid understanding of Engineering design principles for biotherapeutic drug product manufacturing
- Solid understanding of Construction, procurement, project controls, and project scheduling
- Strong technical depth, problem-solving capability, communication skills, and decision-making ability in a fast-paced environment
- Passion for driving innovation in equipment and facility design
- This position is located in Wilson, North Carolina, and will require full time on-site support. However, the design of the facility will occur at an Engineering firm with frequent travel (> 75%) required until the project shifts to the plant site of Wilson, NC.
- Lead development and delivery of the logistics area, including specifications and drawings (URS, data sheets, technical specifications, P&IDs, PFDs) supporting large-molecule, aseptic biotherapeutic drug product operations
- Provide process system ownership and technical leadership for logistics equipment used in biotherapeutic drug product manufacturing
- Assess vendor competency and capabilities; review and influence bid documents; and maintain accountability for project development and execution, including system performance
- Lead detailed design and development of logistics equipment, collaborating with cross-functional partners and strategic equipment vendors
- Serve as the logistics Subject Matter Expert (SME) for large-molecule, aseptic drug product projects, interfacing with A&E firms, construction partners, and equipment suppliers
- Lead and support equipment FAT, SAT, commissioning, qualification, and commercial production line start-up activities
- Resolve complex technical issues during C&Q and ensure system readiness for qualification and commercial operation
- Partner closely with Manufacturing, Facilities, MSAT, Quality, Procurement, E&PS, Automation, Inventory Management, Cold Chain, and EHS to align priorities and accelerate execution
- Ensure alignment across evolving business needs, applying strong stakeholder and partner management skills
- Maintain current knowledge of industry trends and biotherapeutic regulatory expectations
- Apply data-driven insights and market intelligence to guide technical and strategic decisions
- Ensure full compliance with company policies, cGMPs, regulatory requirements, and customer specifications
- Deep process engineering expertise from conceptual design through C&Q to operational readiness in large-molecule biotherapeutic drug product environments
- Experience supporting greenfield or brownfield GMP aseptic manufacturing facility start-ups in the logistics area
- This position is located in Wilson, North Carolina, and will require full time on-site support. However, the design of the facility will occur at an Engineering firm with frequent travel (> 75%) required until the project shifts to the plant site of Wilson, NC.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
- TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
- The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.
What critics are saying
- Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
- The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
- A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.
What makes Johnson & Johnson unique
- J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
- TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
- TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.
Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.
Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.
Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.
Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.